Tesamorelin Dosage: How Much to Take, When & How

Tesamorelin Dosage: How Much to Take, When & How

Overview

Tesamorelin (brand name Egrifta) is a synthetic GHRH analog—a peptide that stimulates your body's natural growth hormone release. Unlike direct growth hormone injections, tesamorelin works through your brain's natural signaling pathways, preserving your body's built-in feedback mechanisms.

The FDA-approved standard dose is straightforward: 2 mg once daily via subcutaneous injection. However, research and clinical practice reveal that effective dosing varies by goal, individual tolerance, and patient population. This guide breaks down exactly how to dose tesamorelin for maximum results and safety.

Cost Context: Tesamorelin ranges from $80–$400 per month depending on source and quantity, making it more accessible than many peptide therapies.

Standard Dosing Protocol

FDA-Approved Dose:

• Amount: 2 mg
• Frequency: Once daily
• Route: Subcutaneous injection
• Timing: Consistent daily time (evening is most common)
• Duration: Ongoing (minimum 26 weeks for documented effects, though clinical use extends longer)

This 2 mg daily dose was established through randomized controlled trials in HIV-infected patients with lipodystrophy and is the only FDA-approved indication. The dose reliably reduces visceral adipose tissue by 15–24% over 26 weeks and increases lean body mass by approximately 1.42 kg.

Why Once Daily? Tesamorelin stimulates pulsatile GH release in a physiologically regulated manner. A single daily injection provides sustained GHRH receptor activation without suppressing your body's natural GH axis—a key advantage over exogenous growth hormone therapy.

Dosing by Goal

While 2 mg daily is the clinical standard, research suggests dose adjustments may be warranted for specific outcomes:

Fat Loss & Body Composition

Dose: 2 mg once daily Duration: Minimum 26 weeks for measurable results Expected Outcome: 15–24% visceral adipose tissue reduction; 1.18 kg trunk fat loss; 4.28% hepatic fat reduction

The evidence is strongest in this category. Meta-analysis of five randomized controlled trials in HIV patients (n=806) consistently shows visceral adipose tissue reduction of -27.71 cm² compared to placebo. However, tesamorelin preferentially targets visceral (deep abdominal) fat over subcutaneous fat—meaningful for metabolic health but not total weight loss.

Muscle & Lean Mass Gain

Dose: 2 mg once daily Duration: 26 weeks minimum Expected Outcome: 1.42 kg lean body mass increase; 1.56–4.86 Hounsfield unit increase in truncal muscle density

Tesamorelin increases muscle area and density through elevated IGF-1 signaling. Effects are robust in HIV populations with abdominal obesity but less characterized in healthy individuals or primary muscle-building contexts. The dose remains 2 mg daily.

Cognitive Enhancement

Dose: 1 mg once daily Duration: 20 weeks Expected Outcome: Modest improvements in memory and executive function; potential GABA elevation in brain tissue

Two human trials support cognitive benefits at a lower dose of 1 mg daily—half the FDA-approved amount. In a 20-week study of 152 adults (ages 55–87, including 66 with mild cognitive impairment), 1 mg daily produced measurable cognitive gains sustained for 10 weeks after discontinuation. This dose is off-label and requires medical supervision.

Metabolic & Liver Health

Dose: 2 mg once daily Duration: 12–26 weeks Expected Outcome: 4.28% hepatic fat reduction; improved triglycerides (37–50 mg/dL reduction); reduced inflammatory markers

The standard 2 mg dose effectively reduces liver fat accumulation and modulates 13 circulating immune proteins (chemokines, cytokines, and T-cell activation markers) in HIV patients with fatty liver disease.

How to Administer

Injection Type: Subcutaneous (under the skin)

Step-by-Step Administration:

1. Preparation

   • Use sterile technique: wash hands and clean the injection site with an alcohol wipe
   • Allow the alcohol to dry completely
   • Reconstitute tesamorelin powder with the provided sterile water or saline according to manufacturer instructions (typically yields 1 mg/mL solution at standard concentration)

2. Site Selection

   • Rotate injection sites to reduce local reactions (common in up to 25% of users)
   • Preferred sites: abdomen, upper arm, or thigh
   • Avoid areas with active inflammation, nodules, or scars
   • Space injections at least 1 inch apart

3. Injection Technique

   • Use a 31-gauge or smaller needle for comfort
   • Insert at a 45–90-degree angle into subcutaneous tissue
   • Inject slowly and steadily
   • Withdraw needle and apply gentle pressure with a clean cotton ball

4. Storage & Stability

   • Store reconstituted solution in the refrigerator (2–8°C) if not used immediately
   • Use within 24 hours of reconstitution unless manufacturer specifies otherwise
   • Keep powder in a cool, dark place prior to reconstitution

Injection Site Reactions: The most common side effect is localized injection site reactions—erythema (redness), pruritus (itching), pain, and induration (hardening)—reported in up to 25% of users. Rotating sites and using proper injection technique minimize this risk.

Cycling & Timing

Dosing Schedule

Standard: 2 mg every 24 hours at the same time daily

• Optimal timing: Evening (within 1–2 hours of bedtime) aligns with natural GH pulsatility
• Consistency: Maintain the same injection time daily for optimal pituitary response

Cycle Length

Minimum: 26 weeks

• Clinical trials demonstrating fat loss and lean mass gains used 26-week (6-month) treatment periods
• Effects continue to improve through weeks 12–26

Extended Use: Many patients continue indefinitely at 2 mg daily

• Ongoing monitoring of IGF-1, fasting glucose, and HbA1c is essential
• No standard "off-cycle" is established, though some practitioners recommend 1–4 week breaks every 6 months to assess response

Loading Phase

Tesamorelin has no formal loading phase. Benefits accumulate over weeks:

• Weeks 1–4: Body begins GHRH receptor re-sensitization; subtle metabolic shifts
• Weeks 4–12: Measurable fat loss and lean mass gain; IGF-1 levels stabilize
• Weeks 12–26: Maximal body composition changes; continued visceral fat reduction

Tapering

Because tesamorelin stimulates endogenous GH (not replacing it), no taper is required. You may discontinue at 2 mg daily without risk of GH-axis suppression—a key safety advantage over exogenous growth hormone.

Beginner vs Advanced Dosing

Beginner Protocol

Population: No prior peptide experience; normal metabolic health; goal is body composition improvement

• Starting dose: 2 mg once daily (standard FDA dose)
• Duration: 26 weeks continuous
• Monitoring: Fasting glucose, HbA1c, IGF-1 every 8–12 weeks
• Timing: Evening injection, consistent daily schedule
• Site rotation: Abdomen, upper arm, thigh—change sites each day

Rationale: The 2 mg daily dose is evidence-based and well-tolerated in clinical trials. No dose escalation is necessary.

Advanced Protocol

Population: Prior peptide experience; metabolic flexibility; off-label goals (cognitive enhancement, extended fat loss); able to manage comprehensive lab work

Option A: Cognitive Focus

• Dose: 1 mg once daily (morning or evening, consistent)
• Duration: 20 weeks
• Monitoring: IGF-1, fasting glucose, cognitive testing (if available)
• Rationale: Lower dose shown in two RCTs for cognitive benefit with reduced metabolic side effects

Option B: Enhanced Body Composition

• Dose: 2 mg once daily for 26 weeks, then assess response
• Extension: If well-tolerated and metabolic markers favorable, continue 2 mg indefinitely OR cycle 2 mg on / 1 week off every 8 weeks
• Monitoring: IGF-1, fasting glucose, HbA1c, lipid panel, waist circumference every 6–8 weeks
• Rationale: Extends benefits while managing long-term IGF-1 elevation risk

Option C: Metabolic Optimization (Liver Health, Anti-Inflammation)

• Dose: 2 mg once daily for 12–26 weeks
• Monitoring: Hepatic ultrasound or MRI (if baseline fatty liver), liver enzymes, IGF-1, inflammatory markers (IL-8, CCL3/4, CRP)
• Rationale: Targets visceral fat and hepatic steatosis with inflammation modulation

Common Dosing Mistakes

1. Underdosing Below 2 mg

   • Mistake: Reducing dose to 1 mg "to be safe" without medical indication
   • Reality: FDA trials used 2 mg; lower doses lack evidence for fat/muscle goals (except cognition)
   • Fix: Use 2 mg daily unless specifically prescribed otherwise by a physician

2. Inconsistent Timing

   • Mistake: Injecting at different times each day (e.g., morning some days, evening others)
   • Reality: Pituitary sensitivity to GHRH is rhythmic; inconsistent timing reduces GH pulsatility
   • Fix: Inject at the same clock time daily, preferably evening

3. Skipping Doses Without Supervision

   • Mistake: Missing 1–2 days and then doubling up or rushing doses
   • Reality: Tesamorelin's effects are dose- and time-dependent; missed doses simply delay results
   • Fix: If a dose is missed, take the next dose at the scheduled time the following day

4. Failing to Rotate Injection Sites

   • Mistake: Injecting in the same abdominal spot repeatedly
   • Reality: Up to 25% of users experience injection site reactions; rotation minimizes lipohypertrophy (fat lumps) and irritation
   • Fix: Use a different site (abdomen → arm → thigh → rotate) each day

5. Inadequate Monitoring

   • Mistake: Taking tesamorelin without regular IGF-1 and fasting glucose checks
   • Reality: Tesamorelin elevates both; clinically significant glucose dysregulation can occur in pre-diabetic individuals
   • Fix: Check IGF-1, fasting glucose, and HbA1c every 8–12 weeks; adjust if IGF-1 exceeds normal range or fasting glucose rises >20 mg/dL

6. Stopping Too Early

   • Mistake: Discontinuing after 8–12 weeks expecting full results
   • Reality: Meaningful fat loss and lean mass gain require 26 weeks minimum
   • Fix: Commit to a 26-week cycle before evaluating efficacy

7. Combining Without Guidance

   • Mistake: Stacking tesamorelin with other GH secretagogues (e.g., sermorelin, MK-677) or exogenous GH
   • Reality: Redundant receptor activation and unpredictable IGF-1 elevation
   • Fix: Use tesamorelin monotherapy; any combination requires physician oversight

Dosing Summary Table

Safety Reminders & Medical Necessity

Tesamorelin requires physician supervision. It is an FDA-approved prescription peptide, not over-the-counter. Off-label use outside supervised medical care carries risks of unsupervised IGF-1 elevation and metabolic dysregulation.

Absolute Contraindications:

• Active malignancy
• Pituitary pathology or tumors
• Pregnancy or breastfeeding
• Hypersensitivity to GHRH or any component

Required Monitoring:

• IGF-1 levels (maintain within upper-normal range)
• Fasting blood glucose and HbA1c (screen for diabetes risk)
• Blood pressure and heart rate
• Lipid panel (triglycerides may rise transiently)

This dosage guide is educational content only and does not constitute medical advice. Tesamorelin should only be used under the direct supervision of a qualified healthcare provider. Self-administration without medical oversight is not recommended.

Summary

Tesamorelin dosing is straightforward for most applications: 2 mg once daily via subcutaneous injection, with effects emerging over 26 weeks. Cognitive applications may use a lower 1 mg daily dose. Consistent timing, site rotation, and regular monitoring of IGF-1 and glucose are essential. Costs range from $80–$400 monthly, and the compound requires a prescription and physician oversight.

Follow the protocols outlined above, avoid common mistakes, and work with a knowledgeable healthcare provider to optimize results while maintaining metabolic safety.